Study of Skin Toxicity of Cetuximab: Find a Link Between Skin Inflammation and Tumor Response
Status:
Completed
Trial end date:
2016-03-03
Target enrollment:
Participant gender:
Summary
Colon cancer is one of the most common cancers in France with more than 36,000 new cases per
year. Despite significant advances in therapeutic care, the prognosis of colon cancers with
metastases remains bad. The treatment of metastatic disease is based on chemotherapy coupled
with therapeutic antibodies. The most commonly used are anti-EGFR (Epidermal Growth Factor
Receptor), which allowed a significant increase in patient survival. They are responsible for
skin toxicity in the form of an acneiform rash which can be debilitating for patients and
require discontinuation of treatment. However, this toxicity is strongly correlated with
treatment efficacy. Understanding the mechanisms of cutaneous side effects of anti-EGFR is
therefore a major challenge to treat and better understand the association with treatment
efficacy.
The objective of this study is to investigate a link between cutaneous inflammatory response
in patients treated with anti-EGFR, serum level of anti-EGFR and treatment efficacy. It will
be conducted systematic consultations dermatology, skin biopsies and blood samples in
patients treated with anti-EGFR. From biopsies, it will be searched by an infiltration of
inflammatory cells and expression of genes involved in skin inflammation.